摘要
Abstract
Objective To evaluate the clinical efficacy and safety of levosimendan in treating senile chronic heart failure. Methods Sixty-four cases of senile chronic heart failure hospitalized in the cardiology department of our hospital from January 2015 to January 2016 were randomly divided into the levosimendan group and basic treatment group ,32 cases in each group. The basic treatment group was given the regular anti-cardiac failure treatment of digitalis,furosemide,ACEI/ARB,spironolactone,β-blockers and trimetazidin;while the levosimendan group was given levosimendan injection by microinfusion pump with a speed of 0.1μg/(kg·min) for consecutive 24 h based on the basis of basic treatment. Blood pressure,heart rate,heart function,24 h urine volume,potassium,natrium and chloride ions,hepatorenal function,pro-BNP,changes of LVEDd,LVESd,LVEF and CI be-fore treatment and after 7 d treatment were observed in both groups. Results Compared with before treatment,LVEDd and LVESd after 7 d treatment in the two groups were decreased,the pro-BNP level was decreased,LVEF and CI were increased,the dif ferences were statistically significant (P<0.05). Compared with the basic treatment group,the blood pressure and heart rate after 7 d treatment in the levosimendan group were decreased,the cardiac function was improved,24 h urine volume was increased,pro-BNP was declined,LVEDd and LVESd were decreased,while CI was increased,the differences were statistically significant(P<0.05);the total effective rate in the levosimendan group was 75.0%(24/32),which was higher than 68.8%(22/32),the difference was statistically significant(P<0.05). There were no serious adverse reactions in both groups. Conclusion Levosimendan injection for treating senile chronic heart failure can improve the treatment effect with good safety.关键词
心力衰竭/老年人/利钠肽,脑/治疗结果/左西孟旦注射液Key words
Heart failure/Aged/Natriuretic peptide, brain/Treatment outcome/Levosimendan injection
